{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:05:43Z","timestamp":1793189143569,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100006096","name":"Shiraz Transplant Research Center, Shiraz University of Medical Sciences","doi-asserted-by":"publisher","award":["30102"],"award-info":[{"award-number":["30102"]}],"id":[{"id":"10.13039\/501100006096","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-24828-5","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:42:14Z","timestamp":1763635334000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Design, synthesis, and biological evaluation of novel 6-(4-aminopiperidin-1-yl)-substituted benzyl-3-methylpyrimidine-2,4(1H,3H)-dione derivatives as potential anticancer agents targeting thymidylate synthase"],"prefix":"10.1038","volume":"15","author":[{"given":"Ladan","family":"Baziar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaheh","family":"Ataollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yousif","family":"Abdulkadhim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Abdolahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Poustforoosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Zare","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mina","family":"Emami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam Moghtader","family":"Mansouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Emami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soghra","family":"Khabnadideh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"2","key":"24828_CR1","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1093\/annonc\/mdw604","volume":"28","author":"NG Zaorsky","year":"2017","unstructured":"Zaorsky, N. G. et al. Causes of death among cancer patients. Ann. Oncol. 28 (2), 400\u2013407 (2017).","journal-title":"Ann. Oncol."},{"issue":"4","key":"24828_CR2","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1002\/ijc.33588","volume":"149","author":"J Ferlay","year":"2021","unstructured":"Ferlay, J. et al. Cancer statistics for the year 2020: an overview. Int. J. Cancer. 149 (4), 778\u2013789 (2021).","journal-title":"Int. J. Cancer"},{"issue":"5","key":"24828_CR3","doi-asserted-by":"publisher","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay, J. et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer. 136 (5), E359\u2013E386 (2015).","journal-title":"Int. J. Cancer"},{"key":"24828_CR4","doi-asserted-by":"crossref","unstructured":"Compton, C. The nature and origins of cancer, in Cancer: the Enemy from Within: A Comprehensive Textbook of Cancer\u2019s Causes, Complexities and Consequences. Springer. 1\u201323. (2020).","DOI":"10.1007\/978-3-030-40651-6_1"},{"issue":"1","key":"24828_CR5","doi-asserted-by":"publisher","first-page":"5651","DOI":"10.1038\/s41467-022-33351-4","volume":"13","author":"F Ma","year":"2022","unstructured":"Ma, F., Laster, K. & Dong, Z. The comparison of cancer gene mutation frequencies in Chinese and US patient populations. Nat. Commun. 13 (1), 5651 (2022).","journal-title":"Nat. Commun."},{"issue":"4","key":"24828_CR6","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2174\/0115734064278334231211054053","volume":"20","author":"T Biswas","year":"2024","unstructured":"Biswas, T. et al. Nitrogen-fused heterocycles: empowering anticancer drug discovery. Med. Chem. 20 (4), 369\u2013384 (2024).","journal-title":"Med. Chem."},{"issue":"2","key":"24828_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.3390\/ph16020299","volume":"16","author":"A Kumar","year":"2023","unstructured":"Kumar, A. et al. Nitrogen containing heterocycles as anticancer agents: a medicinal chemistry perspective. Pharmaceuticals 16 (2), 299 (2023).","journal-title":"Pharmaceuticals"},{"key":"24828_CR8","doi-asserted-by":"crossref","unstructured":"Frank, \u00c9. & Sz\u0151ll\u0151si, G. Nitrogen-containing heterocycles as significant molecular scaffolds for medicinal and other applications. MDPI. p. 4617. (2021).","DOI":"10.3390\/molecules26154617"},{"issue":"10","key":"24828_CR9","doi-asserted-by":"publisher","first-page":"6872","DOI":"10.1039\/D3RA00056G","volume":"13","author":"A Kumar","year":"2023","unstructured":"Kumar, A. et al. Medicinal chemistry perspective of pyrido [2, 3-d] pyrimidines as anticancer agents. RSC Adv. 13 (10), 6872\u20136908 (2023).","journal-title":"RSC Adv."},{"issue":"1","key":"24828_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.2174\/1573406418666220509100356","volume":"19","author":"R Natarajan","year":"2023","unstructured":"Natarajan, R. et al. Structure-activity relationships of pyrimidine derivatives and their biological activity-A review. Med. Chem. 19 (1), 10\u201330 (2023).","journal-title":"Med. Chem."},{"issue":"1","key":"24828_CR11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13065-024-01228-w","volume":"18","author":"A Kumar","year":"2024","unstructured":"Kumar, A. et al. Synthesis and anticancer evaluation of diaryl pyrido [2, 3-d] pyrimidine\/alkyl substituted pyrido [2, 3-d] pyrimidine derivatives as thymidylate synthase inhibitors. BMC Chem. 18 (1), 161 (2024).","journal-title":"BMC Chem."},{"issue":"3","key":"24828_CR12","doi-asserted-by":"publisher","first-page":"32","DOI":"10.21037\/atm-25-38","volume":"13","author":"M Van Oirschot","year":"2025","unstructured":"Van Oirschot, M. et al. Raltitrexed as a substitute for 5-fluorouracil in combination with pembrolizumab and platinum in a patient with metastatic esophageal squamous cell carcinoma and coronary artery disease: a case report. Annals Translational Med. 13 (3), 32 (2025).","journal-title":"Annals Translational Med."},{"key":"24828_CR13","doi-asserted-by":"publisher","first-page":"115701","DOI":"10.1016\/j.ejmech.2023.115701","volume":"259","author":"K Ahmed","year":"2023","unstructured":"Ahmed, K., Choudhary, M. I. & Saleem, R. S. Z. Heterocyclic pyrimidine derivatives as promising antibacterial agents. Eur. J. Med. Chem. 259, 115701 (2023).","journal-title":"Eur. J. Med. Chem."},{"issue":"19","key":"24828_CR14","doi-asserted-by":"publisher","first-page":"e202205009","DOI":"10.1002\/slct.202205009","volume":"8","author":"N Jeelan Basha","year":"2023","unstructured":"Jeelan Basha, N. & Chandana, T. Synthesis and antiviral efficacy of pyrimidine analogs targeting viral pathways. ChemistrySelect 8 (19), e202205009 (2023).","journal-title":"ChemistrySelect"},{"issue":"11","key":"24828_CR15","doi-asserted-by":"publisher","first-page":"6060","DOI":"10.1039\/D0RA10657G","volume":"11","author":"H ur Rashid","year":"2021","unstructured":"ur Rashid, H. et al. Research developments in the syntheses, anti-inflammatory activities and structure\u2013activity relationships of pyrimidines. RSC Adv. 11 (11), 6060\u20136098 (2021).","journal-title":"RSC Adv."},{"issue":"1","key":"24828_CR16","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s43094-021-00274-8","volume":"7","author":"A Mahapatra","year":"2021","unstructured":"Mahapatra, A., Prasad, T. & Sharma, T. Pyrimidine: a review on anticancer activity with key emphasis on SAR. Future J. Pharm. Sci. 7 (1), 123 (2021).","journal-title":"Future J. Pharm. Sci."},{"issue":"4","key":"24828_CR17","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/17460441.2024.2322990","volume":"19","author":"SM de Pinheiro","year":"2024","unstructured":"de Pinheiro, S. M. Molecular hybridization: a powerful tool for multitarget drug discovery. Expert Opin. Drug Discov. 19 (4), 451\u2013470 (2024).","journal-title":"Expert Opin. Drug Discov."},{"issue":"4","key":"24828_CR18","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1080\/17460441.2021.1850686","volume":"16","author":"Shalini","year":"2021","unstructured":"Shalini & Kumar, V. Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on? Expert Opin. Drug Discov. 16 (4), 335\u2013363 (2021).","journal-title":"Expert Opin. Drug Discov."},{"issue":"1","key":"24828_CR19","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s43094-021-00335-y","volume":"7","author":"MM Abdelshaheed","year":"2021","unstructured":"Abdelshaheed, M. M. et al. Piperidine nucleus in the field of drug discovery. Future J. Pharm. Sci. 7 (1), 188 (2021).","journal-title":"Future J. Pharm. Sci."},{"key":"24828_CR20","doi-asserted-by":"crossref","unstructured":"Vodenkova, S. et al. 5-fluorouracil and Other Fluoropyrimidines in Colorectal Cancer: Past, Present and Future 206,107447 (Pharmacology & therapeutics, 2020).","DOI":"10.1016\/j.pharmthera.2019.107447"},{"issue":"1","key":"24828_CR21","doi-asserted-by":"publisher","first-page":"26538","DOI":"10.1038\/s41598-024-77481-9","volume":"14","author":"L Baziar","year":"2024","unstructured":"Baziar, L. et al. Design, synthesis, biological evaluation and computational studies of 4-Aminopiperidine-3, 4-dihyroquinazoline-2-uracil derivatives as promising antidiabetic agents. Sci. Rep. 14 (1), 26538 (2024).","journal-title":"Sci. Rep."},{"key":"24828_CR22","doi-asserted-by":"publisher","first-page":"137435","DOI":"10.1016\/j.molstruc.2023.137435","volume":"1302","author":"L Baziyar","year":"2024","unstructured":"Baziyar, L. et al. Novel uracil derivatives as anti-cancer agents: design, synthesis, biological evaluation and computational studies. J. Mol. Struct. 1302, 137435 (2024).","journal-title":"J. Mol. Struct."},{"issue":"31","key":"24828_CR23","doi-asserted-by":"publisher","first-page":"18008","DOI":"10.1039\/D0RA02432E","volume":"10","author":"L Huang","year":"2020","unstructured":"Huang, L. et al. Synthesis and biological evaluation of dehydroabietic acid-pyrimidine hybrids as antitumor agents. RSC Adv. 10 (31), 18008\u201318015 (2020).","journal-title":"RSC Adv."},{"issue":"13","key":"24828_CR24","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.3390\/molecules30132707","volume":"30","author":"S Iacob","year":"2025","unstructured":"Iacob, S. et al. Hybrid molecules with purine and pyrimidine derivatives for antitumor therapy: News, Perspectives, and future directions. Molecules 30 (13), 2707 (2025).","journal-title":"Molecules"},{"key":"24828_CR25","doi-asserted-by":"crossref","unstructured":"Sharma, S. et al. A review on pyrimidine-based pharmacophore as a template for the development of hybrid drugs with anticancer potential. Mol. Diversity,29 1\u201323. (2025).","DOI":"10.1007\/s11030-025-11112-x"},{"issue":"1","key":"24828_CR26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1006\/mcpr.1994.1010","volume":"8","author":"RM Elledge","year":"1994","unstructured":"Elledge, R. M. et al. Evaluation of thymidylate synthase RNA expression by polymerase chain reaction. Mol. Cell. Probes. 8 (1), 67\u201372 (1994).","journal-title":"Mol. Cell. Probes"},{"issue":"12","key":"24828_CR27","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1177\/002215540205001207","volume":"50","author":"M Derenzini","year":"2002","unstructured":"Derenzini, M. et al. Evaluation of thymidylate synthase protein expression by Western blotting and immunohistochemistry on human colon carcinoma xenografts in nude mice. J. Histochem. Cytochemistry. 50 (12), 1633\u20131640 (2002).","journal-title":"J. Histochem. Cytochemistry"},{"issue":"3","key":"24828_CR28","doi-asserted-by":"publisher","first-page":"311","DOI":"10.3892\/ol.2022.13431","volume":"24","author":"R Mori","year":"2022","unstructured":"Mori, R. et al. The mechanism underlying resistance to 5-fluorouracil and its reversal by the Inhibition of thymidine phosphorylase in breast cancer cells. Oncol. Lett. 24 (3), 311 (2022).","journal-title":"Oncol. Lett."},{"issue":"1","key":"24828_CR29","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12032-022-01864-z","volume":"40","author":"A Kumar","year":"2022","unstructured":"Kumar, A. et al. Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer. Med. Oncol. 40 (1), 3 (2022).","journal-title":"Med. Oncol."},{"issue":"8","key":"24828_CR30","doi-asserted-by":"publisher","first-page":"5437","DOI":"10.1007\/s00210-024-03020-y","volume":"397","author":"A Sen","year":"2024","unstructured":"Sen, A. & Karati, D. An insight into thymidylate synthase inhibitor as anticancer agents: an explicative review. Naunyn. Schmiedebergs Arch. Pharmacol. 397 (8), 5437\u20135448 (2024).","journal-title":"Naunyn. Schmiedebergs Arch. Pharmacol."},{"key":"24828_CR31","doi-asserted-by":"crossref","unstructured":"Murugavel, S. et al. Synthesis, crystal structure analysis, spectral investigations (NMR, FT-IR, UV), DFT calculations, ADMET studies, molecular docking and anticancer activity of 2-(1-benzyl-5-methyl-1H-1, 2, 3-triazol-4-yl)-4-(2-chlorophenyl)-6-methoxypyridine\u2013a novel potent human topoisomerase II\u03b1 inhibitor. Journal of Molecular Structure. 1176, 729\u2013742 (2019).","DOI":"10.1016\/j.molstruc.2018.09.010"},{"key":"24828_CR32","doi-asserted-by":"publisher","first-page":"114683","DOI":"10.1016\/j.ejmech.2022.114683","volume":"243","author":"MD Parenti","year":"2022","unstructured":"Parenti, M. D. et al. Discovery of the 4-aminopiperidine-based compound EM127 for the site-specific covalent Inhibition of SMYD3. Eur. J. Med. Chem. 243, 114683 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"24828_CR33","doi-asserted-by":"crossref","unstructured":"Zhang, J. J. et al. Design, Synthesis and Biological Evaluation of Novel 4-aminopiperidine Derivatives as SMO\/ERK Dual Inhibitors. Bioorganic & Medicinal Chemistry.   74, 117051 (2022).","DOI":"10.1016\/j.bmc.2022.117051"},{"issue":"5","key":"24828_CR34","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/molecules27051643","volume":"27","author":"D Benedetto Tiz","year":"2022","unstructured":"Benedetto Tiz, D. et al. New halogen-containing drugs approved by FDA in 2021: an overview on their syntheses and pharmaceutical use. Molecules 27 (5), 1643 (2022).","journal-title":"Molecules"},{"issue":"8","key":"24828_CR35","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/ph16081162","volume":"16","author":"G Shabir","year":"2023","unstructured":"Shabir, G. et al. Chemistry and Pharmacology of fluorinated drugs approved by the FDA (2016\u20132022). Pharmaceuticals 16 (8), 1162 (2023).","journal-title":"Pharmaceuticals"},{"key":"24828_CR36","doi-asserted-by":"crossref","unstructured":"Zare, S. et al. 6-Bromoquinazoline Derivatives as Potent Anticancer Agents: Synthesis, Cytotoxic Evaluation, and Computational Studies. Chemistry & Biodiversity. 20(7),  e202201245 (2023).","DOI":"10.1002\/cbdv.202201245"},{"key":"24828_CR37","doi-asserted-by":"publisher","first-page":"136622","DOI":"10.1016\/j.molstruc.2023.136622","volume":"1295","author":"E Ataollahi","year":"2024","unstructured":"Ataollahi, E. et al. Novel Quinazolinone derivatives as anticancer agents: Design, synthesis, biological evaluation and computational studies. J. Mol. Struct. 1295, 136622 (2024).","journal-title":"J. Mol. Struct."},{"issue":"7","key":"24828_CR38","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1021\/bi002413i","volume":"40","author":"J Phan","year":"2001","unstructured":"Phan, J. et al. Human thymidylate synthase is in the closed conformation when complexed with dUMP and raltitrexed, an antifolate drug. Biochemistry 40 (7), 1897\u20131902 (2001).","journal-title":"Biochemistry"},{"key":"24828_CR39","doi-asserted-by":"crossref","unstructured":"Emami, L. et al. In-silico screening of Staphylococcus aureus antibacterial agents based on Isatin scaffold: QSAR, molecular docking, molecular dynamics simulation and DFT analysis. Molecular Physics. e2398134 (2024).","DOI":"10.1080\/00268976.2024.2398134"},{"issue":"1","key":"24828_CR40","doi-asserted-by":"publisher","first-page":"7749","DOI":"10.1038\/s41598-024-58485-x","volume":"14","author":"F Zare","year":"2024","unstructured":"Zare, F. et al. A combination of virtual screening, molecular dynamics simulation, MM\/PBSA, ADMET, and DFT calculations to identify a potential DPP4 inhibitor. Sci. Rep. 14 (1), 7749 (2024).","journal-title":"Sci. Rep."},{"issue":"02","key":"24828_CR41","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1055\/a-2235-8845","volume":"74","author":"A Poustforoosh","year":"2024","unstructured":"Poustforoosh, A. et al. Correction: Structure-Based drug design for targeting IRE1: an in Silico approach for treatment of cancer. Drug Res. 74 (02), e1\u2013e1 (2024).","journal-title":"Drug Res."},{"key":"24828_CR42","doi-asserted-by":"crossref","unstructured":"Poustforoosh, A. Optimizing kinase and PARP inhibitor combinations through machine learning and in Silico approaches for targeted brain cancer therapy. Mol. Diversity 29 1\u201311 (2025).","DOI":"10.1007\/s11030-025-11114-9"},{"key":"24828_CR43","doi-asserted-by":"publisher","first-page":"125338","DOI":"10.1016\/j.molliq.2024.125338","volume":"408","author":"A Poustforoosh","year":"2024","unstructured":"Poustforoosh, A. The impact of cationic\/anionic ratio on the physicochemical aspects of catanionic niosomes as a promising carrier for anticancer drugs. J. Mol. Liq. 408, 125338 (2024).","journal-title":"J. Mol. Liq."},{"key":"24828_CR44","doi-asserted-by":"crossref","unstructured":"Poustforoosh, A. Scaffold Hopping Method for Design and Development of Potential Allosteric AKT Inhibitors. Molecular Biotechnology. 1\u201315 (2024).","DOI":"10.1007\/s12033-024-01307-2"},{"issue":"1","key":"24828_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13065-023-01106-x","volume":"18","author":"L Emami","year":"2024","unstructured":"Emami, L. et al. Synthesis, design, biological evaluation, and computational analysis of some novel uracil-azole derivatives as cytotoxic agents. BMC Chem. 18 (1), 3\u20133 (2024). View in Scopus","journal-title":"BMC Chem."},{"issue":"4","key":"24828_CR46","first-page":"791","volume":"7","author":"H Tandon","year":"2019","unstructured":"Tandon, H., Chakraborty, T. & Suhag, V. A brief review on importance of DFT in drug design. Res. Med. Eng. Sci. 7 (4), 791\u2013795 (2019).","journal-title":"Res. Med. Eng. Sci."},{"key":"24828_CR47","doi-asserted-by":"publisher","first-page":"121863","DOI":"10.1016\/j.molliq.2023.121863","volume":"382","author":"S Selvakumari","year":"2023","unstructured":"Selvakumari, S. et al. Solvent effect on molecular, electronic parameters, topological analysis and Fukui function evaluation with biological studies of Imidazo [1, 2-a] pyridine-8-carboxylic acid. J. Mol. Liq. 382, 121863 (2023).","journal-title":"J. Mol. Liq."},{"issue":"2","key":"24828_CR48","first-page":"153","volume":"1","author":"JS Murray","year":"2011","unstructured":"Murray, J. S. & Politzer, P. The electrostatic potential: an overview. Wiley Interdisciplinary Reviews: Comput. Mol. Sci. 1 (2), 153\u2013163 (2011).","journal-title":"Wiley Interdisciplinary Reviews: Comput. Mol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24828-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24828-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24828-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T10:42:18Z","timestamp":1763635338000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-24828-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["24828"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-24828-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"3 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"40991"}}